

## ARNOLD &amp; PORTER LLP

202.942.5000  
202.942.5999 Fax  
555 Twelfth Street, NW  
Washington, DC 20004-1206



December 15, 2004

Mail Stop Issue Fee  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Re: U.S. Application No. 09/338,063  
Filed: June 23, 1999  
Title: Monoclonal Antibodies that Bind OCIF  
Applicants: GOTO *et al.*  
Atty. Docket: 16991.005

Sir:

The following documents are forwarded herewith for appropriate action by the U.S. Patent and Trademark Office (PTO):

1. a Supplemental Summary of Examiner Interview;
2. a photocopy of a postcard date-stamped by the OIPE on November 12, 2003; and
3. a return postcard.

Please stamp the attached postcard with the filing date of these documents and return it to our courier.

In the event that extensions of time beyond those petitioned for herewith are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned. Applicants do not believe any fees are due in conjunction with this filing. However, if any fees are required in the present application, including any fees for extensions of time, then the Commissioner is hereby authorized to charge such fees to Arnold & Porter LLP Deposit Account No. 50-2387 referencing matter number 16991.005. A duplicate copy of this letter is enclosed.

Respectfully submitted,

A handwritten signature in cursive script that reads "Kristan L. Lansbery".

David R. Marsh (Reg. Attorney No. 41,408)  
Kristan L. Lansbery (Reg. Agent No. 53,183)

Enclosures



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

GOTO *et al.*

Appln. No.: 09/338,063

Filed: June 23, 1999

For: *Monoclonal Antibodies that Bind*  
*OCIF*

Art Unit: 1644

Examiner: G. Ewoldt

Atty. Docket: 16991.005

Confirmation No.: 9916

**Supplemental Summary of Examiner Interview**

**Mail Stop Issue Fee**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

On December 2, 2004, Applicants' representatives filed a Summary of Examiner Interview in the above-referenced application. Applicants' representatives subsequently noted typographical errors in some of the dates cited in the Summary of Examiner Interview. To avoid any possible confusion, a corrected version of the text of the Summary of Examiner Interview, with the corrected dates noted in bold text, is submitted below:

In a telephone interview with Examiner Gerald R. Ewoldt, Ph.D. on **November 30, 2004**, the Examiner stated that the substitute specification, filed on November 12, 2003, should be entered. Applicants agree with the decision to enter the substitute specification and understand that the other items filed on **November 12, 2003**, including a substitute sequence listing, will also be entered. If this understanding is not correct, Applicants respectfully request notification.

The Notice of Allowability, mailed on March 1, 2004, was responsive to Applicants' October 14, 2003 filing, despite the intervening submission of, *inter alia*, the substitute specification on November 12, 2003.

Applicants note that in the Response to Rule 312 Communication, mailed on **October 20, 2004**, the Office indicated that the amendment would be entered in part. Applicants did not receive the Response to Rule 312 Communication until after the issue fee for the above-identified application was paid on **June 1, 2004**, the due date. In order to expedite issuance, Applicants will not pursue the amendments requested, but not entered, in the Amendment After Allowance, filed on March 10, 2004. Applicants reserve the right to pursue the amendments in the Amendment After Allowance in priority applications and continuing applications without prejudice.

Should the Examiner have any questions regarding the above-identified application or if the Applicants are wrong to believe that the subject matter of the **November 12, 2003** filing was entered, the Examiner is invited to telephone the undersigned.

Respectfully submitted,



David R. Marsh (Reg. Attorney No. 41,408)  
Kristan L. Lansbery (Reg. Agent No. 53,183)

Date: December 15, 2004

ARNOLD & PORTER LLP  
555 Twelfth Street, N.W.  
Washington, D.C. 20004-1206  
(202) 942-5186 telephone  
(202) 942-5999 facsimile



Atty Docket No: 16991.005  
Date: November 12, 2003

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): GOTO *et al.*  
Appln. No.: 09/338,063  
Filing Date: June 23, 1999  
Title: Monoclonal Antibodies That Bind OCIF


Art Unit: 1644  
Examiner: Gerald R. Ewoldt  
Confirmation No.: 9916

Commissioner for Patents  
P.O. Box 1450, Alexandria, VA 22313-1450

Sir:

Please place the U.S. Patent & Trademark Office receipt stamp hereon to acknowledge receipt of the following:

1. a Transmittal Letter (in duplicate);
2. a Submission of Substitute Specification & Abstract;
3. a marked-up version of the substitute specification (63 pages plus 1 page Abstract);
4. a clean version of the substitute specification (61 pages plus 1 page Abstract);
5. a Statement Regarding Sequence Submission;
6. a paper copy of a substitute sequence listing (81 pages);
7. a sequence listing in Computer Readable Form (CRF), on floppy diskette;
8. a Letter to PTO Draftsperson: Submission of Formal Drawings;
9. twelve (12) sheets of formal drawings (Figures 1A, 1B, 2, 3, 4A, 4B, and 5-15);
10. a Request to Correct Title in PALM including a marked-up copy of the Notice of Allowance and Fee(s) Due Form; and
11. a return postcard.



Return postcard to: Danielle M. Edwards (Room 980)